12:53 PM
 | 
Aug 13, 2018
 |  BC Extra  |  Company News

Amicus prices Galafold at $315k per year

Amicus Therapeutics Inc. (NASDAQ:FOLD) said Monday that it will price Galafold migalastat at $315,000 per year and vowed to limit annual price increases of the Fabry disease drug to the rate of inflation.

On Friday, FDA granted accelerated approval to Galafold to treat Fabry disease in...

Read the full 207 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >